Liver injury in COVID-19: management and challenges

Zhang, C; Shi, Lei; Wang, Fu Sheng

doi:10.1016/s2468-1253(20)30057-1

Cited by 1,695 publications

(2,142 citation statements)

References 13 publications

Supporting

Mentioning

1,842

Contrasting

Unclassified

123

Order By: Relevance

“…2 Liver abnormalities in patients with COVID-19 might be due to viral infection in liver cells but could also be due to other causes such as drug toxicity and systemic inflammation. 4 Data suggest that liver injury is more prevalent in severe cases than in mild cases of COVID-19. 4 However, data about other underlying chronic liver conditions such as non-alcoholic fatty liver disease, alcohol-related liver disease, and autoimmune hepatitis, and their effect on prognosis of COVID-19 needs to be further evaluated.…”

Section: Implications Of Covid-19 For Patients With Pre-existing Digementioning

confidence: 99%

“…4 Data suggest that liver injury is more prevalent in severe cases than in mild cases of COVID-19. 4 However, data about other underlying chronic liver conditions such as non-alcoholic fatty liver disease, alcohol-related liver disease, and autoimmune hepatitis, and their effect on prognosis of COVID-19 needs to be further evaluated.…”

Section: Implications Of Covid-19 For Patients With Pre-existing Digementioning

confidence: 99%

See 1 more Smart Citation

Implications of COVID-19 for patients with pre-existing digestive diseases

Mao

Liang

Shen

et al. 2020

The Lancet Gastroenterology & Hepatology

301

257

View full text Add to dashboard Cite

Section: Implications Of Covid-19 For Patients With Pre-existing Digementioning

confidence: 99%

Section: Implications Of Covid-19 For Patients With Pre-existing Digementioning

confidence: 99%

Implications of COVID-19 for patients with pre-existing digestive diseases

Mao

Liang

Shen

et al. 2020

The Lancet Gastroenterology & Hepatology

301

257

View full text Add to dashboard Cite

“…Nevertheless, it is yet unknown whether these hemostatic changes are a specific effect of SARS-CoV-2 or are a consequence of cytokine storm that precipitates the onset of systemic inflammatory response syndrome (SIRS), as observed in other viral disease (30)(31)(32)(33). Another consideration which has not yet been investigated is that the hemostatic changes seen with COVID-19 infection are related to liver dysfunction (34). A recent study reported 3 cases with severe COVID-19 and cerebral infarction, one associated with bilateral limb ischemia, in the setting of elevated antiphospholipid antibodies.…”

Section: Covid-19 and Hemostasis Parametersmentioning

confidence: 99%

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Bikdeli

Madhavan

Jiménez

et al. 2020

Journal of the American College of Cardiology

2,704

3,005

View full text Add to dashboard Cite

Patients with acute respiratory distress syndrome due to infection with the novel coronavirus SARS-COV2 are currently considered at high risk of developing thromboembolic complications in both venous and arterial vessels. The use of anticoagulants for preventive or curative purposes should be considered to reduce the risk of thromboembolic events. We report a case of a patient with severe COVID-19 acute respiratory distress syndrome who consecutively developed a right femoral deep vein thrombosis related to the femoral central line and acute ischemia of the left upper limb related to a radial arterial line. He was under a therapeutic dose of low molecular weight heparin twice a day three days before. The femoral vein was free of thrombosis while the central line was placed under a duplex ultrasound. Thromboembolic events can occur in patients with severe COVID-19 despite therapeutic anticoagulants. Close monitoring of vascular access with duplex ultrasound may be required.

show abstract

“…Data from two independent cohorts revealed significant enrichment of ACE2 expression in cholangiocytes (59.7% of cells) compared to hepatocytes (2.6% of cells) suggesting that SARS-CoV-2 might directly bind to ACE2-positive cholangiocytes to dysregulate liver function [21]. Although ACE2 is highly expressed in bile duct cells, recent works suggest that gamma-glutamyl transferase (GGT) was elevated in 54% of COVID-19 patients, whereas only 1.8% of patients (1/56) had elevated alkaline phosphatase level [22]. Elsewhere, pathological analysis of hepatic tissue from a patient who died from COVID-19 did not find viral inclusions in the liver [23].…”

Section: Covid-19 and The Livermentioning

confidence: 99%